ACOR Financial Facts

Selling, general and administrative: 46.89M
Research and development: 14.52M
See Full Income Statement

Non-current portion of deferred license revenue: 57.36M
Non-current portion of revenue interest liability: 344K
See Full Balance Sheet

Acorda Therapeutics, Inc. (ACOR) Earnings

  |   Expand Research on ACOR
Next EPS Date 8/1/14 *Est. EPS Growth Rate +133.3% *Last Qtr.
Average EPS % Beat Rate +141.5% Revenue Growth Rate +29.2% *Last Qtr.
Average % Move 1-Wk after EPS +0.7% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/4/11 Q311 $0.40$0.73 -$0.33$93.03M$90.78M N/A Details
10/31/13 Q313 $0.36$0.13 +$0.23$84.92M$90.01M N/A Details
2/13/14 Q413 $0.32$0.18 +$0.14$92.59M$89.96M N/A Details
8/1/13 Q213 $0.25$0.09 +$0.16$87.05M$82.57M N/A Details
5/6/14 Q114 $0.21$0.09 +$0.12$80.52M$81.3M N/A Details
5/2/13 Q113 $0.09$0.13 -$0.04$62.3M$80.71M N/A Details
2/13/13 Q412 $0.24$0.15 +$0.09$81.47M$78.9M N/A Details
10/31/12 Q312 $0.38$0.10 +$0.28$77.44M$75.2M N/A Details